Financial Performance - For the three months ended June 30, 2024, net sales totaled $5.6 million, representing a slight increase from $5.5 million in the same period of 2023, with unit sales of 62,346 and 61,770 respectively[175]. - For the six months ended June 30, 2024, net sales reached $11.3 million, up from $9.3 million in 2023, with unit sales of 133,008 compared to 105,216 in the prior year[175]. - The company reported a net loss of $11.9 million for the three months ended June 30, 2024, compared to a net loss of $3.8 million for the same period in 2023[163]. - As of June 30, 2024, the company had an accumulated deficit of $433.8 million[163]. - Net revenue for Q2 2024 increased by $0.1 million, or 1%, to $5.6 million compared to $5.5 million in Q2 2023[191]. - For the six months ended June 30, 2024, net revenue increased by $2.0 million, or 21%, to $11.3 million compared to $9.3 million in the same period of 2023[201]. - The loss from operations for Q2 2024 was $2.7 million, an improvement of $2.4 million compared to a loss of $5.1 million in Q2 2023[191]. Expenses - Research and development expenses for Q2 2024 were approximately $0.5 million, a decrease of 23% from $0.7 million in Q2 2023[181]. - Selling and marketing expenses for Q2 2024 totaled approximately $3.8 million, down 17% from $4.6 million in Q2 2023[184]. - General and administrative expenses for Q2 2024 were approximately $2.5 million, a decrease of 18% from $3.0 million in Q2 2023[188]. - Total operating expenses for Q2 2024 were $6.8 million, a decrease of 18% from $8.3 million in Q2 2023[191]. - Research and development expenses decreased by $0.4 million, or 30%, from $1.5 million for the six months ended June 30, 2023, to $1.0 million for the six months ended June 30, 2024[203]. - Selling and marketing expenses decreased by $1.8 million, or 19%, from $9.2 million for the six months ended June 30, 2023, to $7.5 million for the six months ended June 30, 2024[204]. - General and administrative expenses decreased by $1.0 million, or 16%, from $6.1 million for the six months ended June 30, 2023, to $5.1 million for the six months ended June 30, 2024[205]. - Interest expense decreased by $0.6 million, or 76%, from $0.8 million for the six months ended June 30, 2023, to $0.2 million for the six months ended June 30, 2024[206]. Cash and Financing - As of June 30, 2024, the company had cash and cash equivalents of $2.8 million, expected to support operations through September 2024[168]. - Net cash used in operating activities was $2.2 million for the six months ended June 30, 2024, compared to $10.1 million for the same period in 2023[210]. - Net cash provided by financing activities for the six months ended June 30, 2024, was $2.5 million, compared to $8.1 million for the same period in 2023[212]. - At June 30, 2024, cash and cash equivalents totaled $2.8 million[208]. - The company raised net proceeds of $6.5 million through the sale of 1,896,286 shares of common stock in the May 2023 Offering[221]. Merger and Agreements - The company has entered into a merger agreement with Insud Pharma, S.L., with each share of common stock to be converted into $1.52 in cash[157]. - The merger is subject to approval by a majority of the outstanding shares at a special meeting scheduled for August 22, 2024[158]. - The company has a line of credit available up to $8.0 million from Insud, with an initial loan advance of $6.5 million made on July 1, 2024[159]. - The minimum committed amount under the Corium Agreement totals $206.7 million for the 10-year period from 2024 through 2033[227]. - The guaranteed minimum revenue requirement for 2024 has been reset to $10.0 million, with a potential increase to $22.5 million per year if the Merger is not consummated[227]. - The Syneos Agreement has a minimum commitment of $2.4 million as of June 30, 2024, with the agreement set to expire on August 23, 2024[231]. - The operating lease commitment for office space in Princeton, New Jersey totals $0.3 million over the remaining 12-month term as of June 30, 2024[231]. - The company did not meet all minimum quantity purchases from Corium in 2021, resulting in penalties as per the agreement[227]. - The Corium Agreement has been amended to extend its term until December 31, 2033, with automatic termination unless mutually agreed otherwise[227]. - The Syneos Agreement was amended on February 1, 2022, to extend its term until August 23, 2024[228]. - The company has the ability to terminate the Syneos Agreement without incurring a termination fee upon timely written notice[228]. Operational Outlook - The company plans to continue its commercialization efforts for Twirla, focusing on increasing uptake through digital advertising and partnerships[164]. - The company has never been profitable since its inception in 1997 and anticipates continued operating losses as it commercializes Twirla[163]. - The company expects to incur significant operating expenses to support the commercialization of Twirla and maintain its sales and marketing infrastructure[223]. Internal Controls - There have been no changes in internal control over financial reporting that materially affected the company during the most recent fiscal quarter[234]. - The company's disclosure controls and procedures were deemed effective as of June 30, 2024, ensuring timely reporting of required information[233].

Group 1 - Kuehn Law is investigating potential claims related to proposed mergers involving Agile Therapeutics, Spirit AeroSystems, and Envestnet to ensure shareholder value maximization and fair processes [1] - Agile Therapeutics will be acquired by Insud Pharma for $1.52 per share in cash [1] - Spirit AeroSystems will sell to Boeing Co. with shareholders receiving $37.25 per share in Boeing common stock [1] - Envestnet will merge with Bain Capital for $63.15 per share in cash [1] Group 2 - UMB Financial Corporation will acquire Heartland Financial USA Inc. in an all-stock deal valued at approximately $2.0 billion [2] - The merger is positioned as a significant event for shareholders, emphasizing the importance of their participation in maintaining market integrity [2] Group 3 - Kuehn Law encourages concerned shareholders to contact them for involvement in safeguarding shareholder interests, with no costs incurred by the investors [3] - Shareholders are advised to act promptly due to the time-sensitive nature of legal rights [3]

Core Viewpoint - Agile Therapeutics has entered into a definitive merger agreement with Insud Pharma's US subsidiary, Exeltis, which will enhance its women's health and contraceptive portfolio, offering shareholders a significant premium on their shares [1][2] Company Overview - Agile Therapeutics is focused on improving women's health through innovative products, notably Twirla, a low-dose combined hormonal contraceptive patch [2][5] - The company has developed a targeted commercial platform to accelerate Twirla's growth while managing operating expenses [2] Merger Details - The merger agreement stipulates that Agile shareholders will receive $1.52 per share, representing a 356% premium to the closing share price on June 25, 2024, with a total enterprise value of approximately $45 million [1][2] - Insud Pharma will provide a line of credit of up to $8 million, secured by Agile's intellectual property, primarily to purchase inventory [3] - The transaction is expected to close in the third quarter of 2024, pending shareholder approval and other customary conditions [3] Strategic Implications - The merger is seen as a strategic move to leverage Exeltis' resources to further develop Twirla and enhance its market presence [2] - Agile's Board of Directors has unanimously approved the transaction, indicating strong internal support for the merger [3] Advisors - H.C. Wainwright & Co. served as the exclusive financial advisor to Agile Therapeutics, while Morgan, Lewis & Bockius LLP acted as its legal advisor [4]

Financial Performance - For the three months ended March 31, 2024, net sales totaled $5.7 million, an increase from $3.8 million for the same period in 2023, representing a growth of approximately 50%[159]. - The company reported a net income of $1.3 million for the three months ended March 31, 2024, compared to a net loss of $5.4 million for the same period in 2023[148]. - Net revenues increased by $1.9 million, or 50%, from $3.8 million in Q1 2023 to $5.7 million in Q1 2024, with unit sales rising by 27,216 units, or 63%[177]. - Net income improved to $1.3 million in Q1 2024 from a net loss of $5.4 million in Q1 2023, representing a positive change of $6.7 million[177]. - Unrealized gain on warrant liability increased to $4.2 million in Q1 2024 from $1.7 million in Q1 2023, a change of $2.5 million[184]. Expenses - Research and development expenses decreased to approximately $0.5 million for the three months ended March 31, 2024, down from $0.8 million in the same period of 2023[164]. - Selling and marketing expenses totaled approximately $3.7 million for the three months ended March 31, 2024, compared to $4.7 million for the same period in 2023, reflecting a reduction in marketing costs[171]. - Cost of product revenues decreased by $0.3 million, or 16%, from $2.0 million in Q1 2023 to $1.7 million in Q1 2024[178]. - Research and development expenses decreased by $0.3 million, or 35%, from $0.8 million in Q1 2023 to $0.5 million in Q1 2024[179]. - Selling and marketing expenses decreased by $1.0 million, or 21%, from $4.7 million in Q1 2023 to $3.7 million in Q1 2024[180]. - General and administrative expenses decreased by $0.5 million, or 15%, from $3.1 million in Q1 2023 to $2.6 million in Q1 2024[181]. Financial Position - The accumulated deficit as of March 31, 2024, was $421.9 million, indicating ongoing financial challenges since inception[148]. - As of March 31, 2024, the company had cash and cash equivalents of $2.6 million, expected to support operations through June 2024[151]. - Net cash used in operating activities was $2.5 million in Q1 2024, compared to $1.6 million in Q1 2023[186]. - Net cash provided by financing activities was $2.5 million in Q1 2024, compared to $0.8 million in Q1 2023[189]. - As of March 31, 2024, cash and cash equivalents totaled $2.6 million[185]. Future Outlook - Future success is contingent upon the ability to obtain additional capital and effectively commercialize Twirla, with substantial doubt about the ability to continue as a going concern[152]. - The company plans to continue its commercialization efforts for Twirla, focusing on increasing uptake through targeted advertising and partnerships[145]. - The company aims to expand coverage and reimbursement for Twirla in the U.S. from private and public third-party payors[146]. - The company expects to incur significant operating expenses related to the commercialization of Twirla and may need to raise additional funds for working capital[200]. - The company recognizes the need for adequate funding to successfully commercialize Twirla and may face operational challenges if unable to secure additional capital[202]. Commitments and Agreements - The minimum committed amount under the Corium Agreement totals $210.1 million for the 10-year period from 2024 through 2033, with a guaranteed minimum revenue requirement of $10.0 million for 2024[205]. - The guaranteed minimum revenue requirement for 2025 and beyond will return to $22.5 million per year under the Corium Agreement[205]. - The company has a minimum commitment of $2.4 million under the Syneos Agreement for sales and marketing services through August 23, 2024[206]. - The operating lease commitment for office space in Princeton, New Jersey totals $0.4 million as of March 31, 2024[207]. Capital Raising and Financing - The company does not have any committed external source of funds and plans to finance cash needs through equity offerings, debt financings, and collaborations[204]. - The company issued warrants representing the right to purchase up to 3,892,572 shares at an exercise price of $3.69, which were later exercised at a reduced price of $1.25, generating gross proceeds of approximately $4.8 million[199]. - New warrants were issued for an aggregate of up to 7,785,144 shares at an exercise price of $1.00, with terms of five years and eighteen months for different portions[199]. Regulatory Obligations - The company is obligated to conduct post-marketing requirements from the FDA and evaluate additional line extensions for Twirla[201].

[Q1 2024 Performance Highlights](index=1&type=section&id=Q1%202024%20Performance%20Highlights) Agile Therapeutics reported strong Q1 2024 growth, with net revenue up 50% to $5.7 million, driven by Twirla demand and reduced operating costs Q1 2024 Key Performance Metrics | Metric | Q1 2024 | vs. Q4 2023 | vs. Q1 2023 | | :--- | :--- | :--- | :--- | | **Net Revenue ($ million)** | $5.7 | +58% | +50% | | **Twirla Demand (Total Cycles)** | 81,088 | +18% | +80% | | **Twirla Factory Sales (Total Cycles)** | 70,662 | +3% | +63% | | **Operating Expenses ($ million)** | $6.8 | +24% | -20% | - The increase in Q1 2024 net revenue was primarily attributed to higher demand for Twirla[3](index=3&type=chunk) - The company's growth strategy focuses on its five-state concentration, expanding its telemedicine reach, and strengthening relationships with planned parenthood organizations[2](index=2&type=chunk) [Q1 2024 Financial Results](index=2&type=section&id=Q1%202024%20Financial%20Results) Agile Therapeutics achieved a Q1 2024 GAAP net income of $1.3 million, a significant turnaround from the prior year's loss, supported by revenue growth Q1 2024 Key Financial Data | Financial Metric | Q1 2024 | Q1 2023 | | :--- | :--- | :--- | | **Net Revenue ($ million)** | $5.7 | $3.8 | | **Cost of Goods Sold (COGS) ($ million)** | $1.7 | $2.0 | | **Total Operating Expenses ($ million)** | $6.8 | $8.5 | | **GAAP Net Income (Loss) ($ million)** | $1.3 | ($5.4) | | **GAAP EPS (basic and diluted)** | $0.28 | ($5.91) | | **Non-GAAP Net Loss ($ million)** | ($2.9) | ($7.1) | | **Non-GAAP Net Loss Per Share** | ($0.63) | ($7.76) | - Cash and cash equivalents were **$2.6 million** as of March 31, 2024, slightly up from **$2.5 million** at the end of 2023[7](index=7&type=chunk) - As of March 31, 2024, the company had **6,856,229 shares** of common stock outstanding[7](index=7&type=chunk) [Corporate Updates and Business Outlook](index=2&type=section&id=Corporate%20Updates%20and%20Business%20Outlook) Agile Therapeutics' stock moved to OTC in March 2024, with optimism for growth from new guidance expanding no-cost contraceptive access for women - As of March 26, 2024, the company's common stock is trading on the **OTC market** under its existing **AGRX** symbol[7](index=7&type=chunk) - The company is optimistic about new guidance from the Biden-Harris Administration announced in January 2024, which aims to expand access to FDA-approved contraceptives like Twirla at no cost for an estimated **49 million women**[7](index=7&type=chunk) - Management plans to explore all strategic opportunities, both internal and external, to advance Twirla's growth and increase shareholder value[2](index=2&type=chunk) [Financial Statements](index=7&type=section&id=Financial%20Statements) The financial statements detail Q1 2024 performance, showing reduced stockholders' deficit and GAAP profitability, with non-GAAP reconciliation provided [Balance Sheets](index=7&type=section&id=Balance%20Sheets) Balance Sheet Summary (in thousands) | Account | March 31, 2024 | December 31, 2023 | | :--- | :--- | :--- | | **Cash and cash equivalents ($ thousands)** | $2,615 | $2,557 | | **Total current assets ($ thousands)** | $11,987 | $9,530 | | **Total assets ($ thousands)** | $12,610 | $10,255 | | **Total current liabilities ($ thousands)** | $21,441 | $20,777 | | **Total liabilities ($ thousands)** | $22,934 | $26,573 | | **Total stockholders' deficit ($ thousands)** | ($10,324) | ($16,318) | [Statement of Operations](index=9&type=section&id=Statement%20of%20Operations) Statement of Operations Summary (in thousands) | Account | Three Months Ended March 31, 2024 | Three Months Ended March 31, 2023 | | :--- | :--- | :--- | | **Revenues, net ($ thousands)** | $5,716 | $3,813 | | **Gross profit ($ thousands)** | $4,036 | $1,810 | | **Total operating expenses ($ thousands)** | $6,793 | $8,518 | | **Loss from operations ($ thousands)** | ($2,757) | ($6,708) | | **Unrealized gain on warrant liability ($ thousands)** | $4,203 | $1,687 | | **Net income (loss) ($ thousands)** | $1,284 | ($5,390) | | **Net income (loss) per share** | $0.28 | ($5.91) | [Reconciliation of GAAP to Non-GAAP Net Loss](index=10&type=section&id=Reconciliation%20of%20GAAP%20to%20Non-GAAP%20Net%20Loss) GAAP to Non-GAAP Reconciliation (in thousands) | Metric | Q1 2024 | Q4 2023 | Q1 2023 | | :--- | :--- | :--- | :--- | | **GAAP net income (loss) ($ thousands)** | $1,284 | ($4,467) | ($5,390) | | **Unrealized gain (loss) on warrant liability ($ thousands)** | $4,203 | ($130) | $1,687 | | **Non-GAAP net loss ($ thousands)** | ($2,919) | ($4,337) | ($7,077) | [About the Company and Product](index=3&type=section&id=About%20the%20Company%20and%20Product) Agile Therapeutics is a women's healthcare company focused on non-daily contraceptive options, featuring its flagship Twirla® once-weekly patch [About Agile Therapeutics, Inc.](index=3&type=section&id=About%20Agile%20Therapeutics%2C%20Inc.) - Agile Therapeutics is a women's healthcare company focused on providing contraceptive options that offer freedom from a daily pill without the commitment of a longer-acting method[8](index=8&type=chunk) [About Twirla®](index=3&type=section&id=About%20Twirla%C2%AE) - Twirla® is a once-weekly combined hormonal contraceptive patch indicated for women with a **BMI < 30 kg/m²**. It is contraindicated in women with a **BMI ≥ 30 kg/m²** and in women over 35 who smoke[9](index=9&type=chunk) [Supplemental Information](index=3&type=section&id=Supplemental%20Information) This section provides context for the report, defining prescription data, explaining non-GAAP financial measures, and including forward-looking statements [About Prescription Data](index=3&type=section&id=About%20Prescription%20Data) - The company sources its prescription data from Symphony Health Solutions. It believes factory sales more closely represent total demand for Twirla as not all non-retail channel data is captured by third-party services[10](index=10&type=chunk)[11](index=11&type=chunk) [Use of Non-GAAP Financial Measures](index=4&type=section&id=Use%20of%20Non-GAAP%20Financial%20Measures) - The company uses **non-GAAP net loss**, which excludes recurring unrealized gains or losses from its warrant liability, to provide what it believes is a more useful measure for period-to-period comparisons of its business operations[12](index=12&type=chunk) [Forward-Looking Statements](index=4&type=section&id=Forward-Looking%20Statements) - The press release contains forward-looking statements regarding the commercialization of Twirla®, market acceptance, future financing, and other strategic plans, which are subject to various risks and uncertainties[14](index=14&type=chunk)[16](index=16&type=chunk)

Financial Performance - As of December 31, 2023, the company reported an accumulated deficit of $423.2 million and a net loss of $14.5 million for the year[305]. - Net sales for the year ended December 31, 2023, totaled $19.6 million, an increase from $10.9 million in 2022, driven by the sale of 248,220 units compared to 114,546 units in the previous year[315]. - The net loss for 2023 was $14.465 million, a decrease from a net loss of $25.412 million in 2022, representing a 43.2% improvement[393]. - Agile Therapeutics reported net revenues of $19.593 million for the year ended December 31, 2023, a 80.1% increase from $10.884 million in 2022[393]. - The company's gross profit for 2023 was $10.615 million, compared to a gross profit of $4.048 million in 2022, reflecting a significant improvement in profitability[393]. - Total operating expenses decreased to $30.499 million in 2023 from $56.604 million in 2022, indicating a reduction of 46.5%[393]. Expenses - The cost of product revenues for 2023 was $9.0 million, up from $6.8 million in 2022[317]. - Research and development expenses decreased significantly to approximately $2.2 million in 2023 from $3.3 million in 2022 and $6.2 million in 2021[321]. - Selling and marketing expenses totaled approximately $17.8 million in 2023, down from $30.4 million in 2022 and $43.4 million in 2021[325]. - General and administrative expenses were approximately $10.5 million in 2023, compared to $11.9 million in 2022 and $14.7 million in 2021[327]. - Interest expense decreased by $1.7 million, from $3.1 million in 2022 to $1.4 million in 2023, due to principal payments made throughout 2023[346]. Cash Flow and Liquidity - The company had cash and cash equivalents of $2.5 million as of December 31, 2023, which is expected to support operations through April 2024[309]. - Net cash used in operating activities was $9.6 million for the year ended December 31, 2023, compared to $35.9 million in 2022[353]. - Cash and cash equivalents decreased to $2.557 million as of December 31, 2023, down from $5.246 million in 2022[391]. - The company has a working capital deficiency and substantial doubt exists about its ability to continue as a going concern[383]. - The company has a working capital deficit of $11.2 million as of December 31, 2023, raising concerns about its liquidity and operational sustainability[404]. Capital Raising and Financing - The company raised net proceeds of approximately $12.2 million by issuing and selling 173,750 shares of common stock under the April 2022 ATM Agreement[358]. - The company raised net proceeds of $6.5 million from the May 2023 Offering by selling 1,896,286 shares of common stock[364]. - In 2022, the company completed a public offering raising net proceeds of $22.0 million through the sale of 382,966 shares of common stock and 150,366 pre-funded warrants[363]. - The Company has a common stock sales agreement allowing for the sale of up to $50.0 million in gross proceeds through "at-the-market" equity offerings[501]. - The Perceptive Credit Agreement allows for a senior secured term loan of up to $35 million, with an interest rate of 15.60% as of December 31, 2023[480]. Strategic Plans and Future Outlook - The company plans to continue focusing on the commercialization of Twirla while exploring opportunities for a second product to reduce operating losses[308]. - Future research and development costs will depend on various factors, including the uncertainties of clinical trials and access to additional capital[323]. - The company anticipates continuing to incur significant operating expenses as it seeks to commercialize Twirla and explore additional product candidates[404]. - The company is exploring strategic alternatives, including potential asset sales and mergers or acquisitions[371]. Inventory and Sales - The company recorded a product return reserve liability of $1.9 million as of December 31, 2023, reflecting the estimation of returns based on sales data[388]. - In 2023, the company had sales to five major customers that accounted for 94% of total revenue, with individual sales of $4.7 million, $3.8 million, $3.7 million, $3.5 million, and $2.8 million[427]. - Total allowances for sales as of December 31, 2023, amounted to $11.206 million, which includes customer credits, rebates, and product returns[442]. Stock and Warrants - The Company issued warrants representing the right to purchase up to 3,892,572 shares of common stock at an exercise price of $3.69 per share, later reduced to $1.25 per share[365]. - As of December 31, 2023, the Company has 5,589,637 common stock warrants outstanding, compared to 1,130,025 in 2022[460]. - The fair value of the Company's warrant liability decreased from $5,934,000 in 2022 to $5,696,000 in 2023[469]. - The significant assumptions for the option pricing model for valuing the Company's warrants as of December 31, 2023 include a volatility of 101.5% - 126.0% and a fair value of common stock at $1.95[468]. Accounting and Compliance - The Company has adopted ASC 718 for stock-based compensation, recognizing compensation cost over the requisite service period[456]. - The Company is evaluating the impact of new accounting standards issued by the FASB, including ASU 2023-07 and ASU 2023-09[462][463]. - The Company has no uncertain tax positions as of December 31, 2023[455].

Financial Data and Key Metrics Changes - Full year 2023 net revenue was $19.6 million, an 80% increase from $10.9 million in 2022 [8] - Operating expenses for full year 2023 were $30.5 million, a 33% decrease from $45.5 million in 2022 [10] - The company closed 2023 with a net loss of $14.5 million, improved from a net loss of $25.4 million in 2022 [18] Business Line Data and Key Metrics Changes - Twirla demand for 2023 was 243,841 total cycles, a 131% increase from 2022 [8] - Twirla factory sales for 2023 were 248,220 total cycles, a 117% increase from 2022 [9] - Fourth quarter 2023 net revenue was $3.6 million, a 46% decrease from $6.7 million in the third quarter [11] Market Data and Key Metrics Changes - The gross-to-net charges in Q4 2023 increased due to higher Medicaid activity, increased returns reserve, and a larger mix of non-retail business [11] - Preliminary Twirla demand numbers for January 2024 showed the highest retail channel cycles in a single month since launch [12] Company Strategy and Development Direction - The company emphasizes partnerships to maximize Twirla's growth potential and is exploring strategic opportunities [13] - The elimination of debt owed to Perceptive Advisors is seen as a significant milestone, providing flexibility for future opportunities [13] Management's Comments on Operating Environment and Future Outlook - Management views the fourth quarter 2023 performance as an anomaly and expects a rebound in early 2024 [11][12] - The company remains optimistic about the Biden administration's efforts to enhance access to no-cost contraception, which could benefit Twirla's growth [15][16] Other Important Information - The company received a final delisting notice from Nasdaq and is now trading on the over-the-counter market [14] - In January 2024, the company raised $4.8 million in gross proceeds through a warrant exchange agreement [18] Q&A Session Summary - No Q&A session was conducted following the prepared remarks [19]

Core Viewpoint - Agile Therapeutics, Inc. is set to report its fourth quarter and full year 2023 financial results on March 28, 2024, followed by a conference call to discuss these results and provide a business update [1]. Group 1: Financial Results Announcement - The company will announce its financial results before the market opens on March 28, 2024 [1]. - A live conference call and webcast will take place at 8:30 a.m. ET to discuss the financial results [1]. - The conference call can be accessed via the Investor Relations section of the Agile Therapeutics website [1]. Group 2: Company Overview - Agile Therapeutics is focused on women's healthcare, aiming to address unmet health needs [2]. - The company's product, Twirla®, is a non-daily prescription contraceptive based on proprietary transdermal patch technology called Skinfusion® [2]. - Twirla® provides women with contraceptive options that do not require daily intake, offering flexibility without long-term commitment [2].

Core Viewpoint - Agile Therapeutics, Inc. is set to report its fourth quarter and full year 2023 financial results on March 28, 2024, followed by a conference call to discuss these results and provide a business update [1]. Group 1: Financial Results Announcement - The company will announce its financial results before the market opens on March 28, 2024 [1]. - A live conference call and webcast will take place at 8:30 a.m. ET to discuss the financial results [1]. - The conference call can be accessed via the Investor Relations section of the Agile Therapeutics website [1]. Group 2: Company Overview - Agile Therapeutics is focused on women's healthcare, addressing unmet health needs with contraceptive options that do not require daily intake [2]. - The company's initial product, Twirla®, is a non-daily prescription contraceptive based on proprietary transdermal patch technology called Skinfusion® [2]. - The company aims to provide women with more flexible contraceptive choices without the commitment of longer-acting methods [2].

Core Viewpoint - Agile Therapeutics, Inc. is set to report its fourth quarter and full year 2023 financial results on March 22, 2024, followed by a conference call to discuss these results and provide a business update [1]. Company Overview - Agile Therapeutics is a women's healthcare company focused on addressing unmet health needs of women today [2]. - The company offers contraceptive options that do not require daily intake, with its initial product, Twirla®, being a non-daily prescription contraceptive based on proprietary transdermal patch technology called Skinfusion® [2].